Patents by Inventor Jennifer Marie Mataraza

Jennifer Marie Mataraza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF
    Publication number: 20160108123
    Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: October 13, 2015
    Publication date: April 21, 2016
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Gerhard Johann Frey, Hwai Wen Chang, Jennifer Marie Mataraza, Glenn Dranoff
  • ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF
    Publication number: 20150259420
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 17, 2015
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
    Publication number: 20150218274
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • ANTIBODY MOLECULES TO PD-1 AND USES THEREOF
    Publication number: 20150210769
    Abstract: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Gordon James Freeman, Arlene Helen Sharpe, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20140017255
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 16, 2014
    Applicant: MEDAREX, L.L.C.
    Inventors: Jennifer Marie MATARAZA, Andrea VAN ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
  • Fully human antibodies to BTLA
    Patent number: 8563694
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 22, 2013
    Assignees: Medarex, Inc., N.V.Organon
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • FULLY HUMAN ANTIBODIES TO BTLA
    Publication number: 20120183565
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicants: N.V. ORGANON, MEDAREX, INC.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc